



Curriculum Vitae

Giovanni Randon

INFORMAZIONI PERSONALI

Giovanni Randon

Fondazione IRCCS
Istituto Nazionale dei Tumori
Prof. Filippo de Braud
Direttore SC Medicina Oncologica 1

Sesso M | Data di nascita 07/03/1989 | Nazionalità italiana

01/11/2016 – 31/10/2021

Diploma di Specializzazione in Oncologia Medica
Università degli Studi di Milano
Scuola di Specializzazione in Oncologia Medica
Fondazione IRCCS Istituto Nazionale dei Tumori INT
Via Venezian, 2, 20133 Milano
- 70/70 con lode

Medico in formazione specialistica

ISTRUZIONE e FORMAZIONE

2008-2015

Laurea in Medicina e Chirurgia
Università degli Studi di Padova
Via VIII Febbraio, 2, 35122 Padova
- 110/110

2013-2015

Istituto Oncologico Veneto IOV-IRCCS
Oncologia Medica 2
Ambulatorio Patologia Ginecologica
Via Gattamelata 64, 35128, Padova

Studente frequentatore

2003-2008

Diploma di Maturità
Liceo Classico "Tito Livio"
Riviera Tito Livio, 9, 35123, Padova
- 100/100

Lingua madre Italiano

Altre lingue

	COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
Inglese	C1	C1	C1	C1	C1
First Certificate English (2007)					
Tedesco	B1	B1	B1	B1	B1
Goethe Zertifikat B1 (2008)					

Livelli: A1/A2: Utente base - B1/B2: Utente intermedio - C1/C2: Utente avanzato
 Quadro Comune Europeo di Riferimento delle Lingue

Patente di guida Patente di guida
 B

Pubblicazioni

1. **Randon G**, Nicoletto MO, Milite N, Muggia F, Conte P. Squamous cell carcinoma of the oral cavity in a woman with a 9-year history of ovarian cancer: is exposure to pegylated liposomal Doxorubicin a factor? *Oncologist*. 2014 Apr;19(4):429.
2. Indraccolo S, **Randon G**, Zulato E, Nardin M, Aliberti C, Pomerri F, Casarin A, Nicoletto MO. Metformin: a modulator of bevacizumab activity in cancer? A case report. *Cancer Biol Ther*. 2015;16(2):210-4.
3. Nicoletto MO, Baldoni A, Casarin A, **Randon G**, Nardin M, Baretta Z, Lardelli P, Nieto A, Alfaro V, Rigamonti C, Conte PF. Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer. *Tumori*. 2015 Sep-Oct;101(5):506-10.
4. Nicoletto MO, Casarin A, Baldoni A, Rulli E, Tasca G, Baretta Z, Artioli G, Lombardi G, Cappetta A, Floriani I, **Randon G**, Valpione S, Litta P, Conte P, Mocellin S, Aliberti C. Intraperitoneal Chemotherapy in Patients Pretreated for Ovarian Cancer Matched with Patients Treated with Parenteral Chemotherapy. *Anticancer Res*. 2016 Dec;36(12):6541-6546.
5. Nichetti F, Lobefaro R, Pagani F, **Randon G**, Corti F, de Braud F, Celio L, Platania M. Systemic strategy at the patient's service": a congress report on supportive care in oncology. *Tumori*. 2017 Jul 27:0.
6. Morano F, Corallo S, Niger M, Barault L, Milione M, Berenato R, Moretto R, **Randon G**, Antista M, Belfiore A, Raimondi A, Nichetti F, Martinetti A, Battaglia L, Perrone F, Prunerì G, Falcone A, Di Bartolomeo M, de Braud F, Di Nicolantonio F, Cremolini C, Pietrantonio F. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. *Ann Oncol*. 2018 Aug 1;29(8):1800-1806.
7. Cimminiello C, Indini A, Di Guardo L, Prisciandaro M, **Randon G**, Tolomio E, De Braud F, Del Vecchio M. Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience. *Melanoma Res*. 2018 Dec 4.
8. Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, **Randon G**, De Braud F, Del Vecchio M. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. *J Cancer Res Clin Oncol*. 2019 Feb;145(2):511-521.

9. Pietrantonio F, Cotsoglou C, Fucà G, Lo Vullo S, Nichetti F, Milione M, Coppa J, Vaiani M, Alessi A, Prisciandaro M, Droz-Dit Busset M, Morano F, Corallo S, Lazzati S, Antista M, Mennitto A, **Randon G**, Raimondi A, Belfiore A, Padovano B, Perrone F, Mariani L, Di Bartolomeo M, de Braud F, Mazzaferro V. Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. *Clin Colorectal Cancer*. 2019 Mar;18(1):34-43.e6.
10. Cona MS, Lecchi M, Cresta S, Damian S, Del Vecchio M, Necchi A, Poggi MM, Raggi D, **Randon G**, Ratta R, Signorelli D, Vernieri C, de Braud F, Verderio P, Di Nicola M. Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. *Cancers (Basel)*. 2019 Feb 14;11(2).
11. **Randon G**, Fucà G, Rossini D, Raimondi A, Pagani F, Perrone F, Tamborini E, Busico A, Peverelli G, Morano F, Niger M, Antista M, Corallo S, Saggio S, Borelli B, Zucchelli G, Milione M, Prunerì G, Di Bartolomeo M, Falcone A, de Braud F, Cremolini C, Pietrantonio F. Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. *Sci Rep*. 2019 Feb 27;9(1):2858.
12. Raimondi A, Corallo S, Niger M, Antista M, **Randon G**, Morano F, Milione M, Kusamura S, Baratti D, Guaglio M, Cremolini C, Marmorino F, Di Bartolomeo M, Deraco M, De Braud F, Pietrantonio F. Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. *Clin Colorectal Cancer*. 2019 Apr 1. pii: S1533-0028(19)30097-0.
13. Raimondi A, Corallo S, Niger M, Antista M, **Randon G**, Morano F, Milione M, Kusamura S, Baratti D, Guaglio M, Cremolini C, Marmorino F, Di Bartolomeo M, Deraco M, De Braud F, Pietrantonio F. Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. *Clin Colorectal Cancer*. 2019 Jun;18(2):e179-e190.
14. Sangaletti S, Talarico G, Chiodoni C, Cappetti B, Botti L, Portararo P, Gulino A, Consonni FM, Sica A, **Randon G**, Di Nicola M, Tripodo C, Colombo MP. SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities. *Front Immunol*. 2019 Jun 20;10:1369.
15. Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, **Randon G**, De Braud F, Del Vecchio M. Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma. *Tumori*. 2019 Dec;105(6):465-473.
16. Raimondi A, **Randon G**, Sepe P, Claps M, Verzoni E, de Braud F, Procopio G. The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice. *Int J Mol Sci*. 2019 Aug 30;20(17):4263.
17. Galli G, De Toma A, Pagani F, **Randon G**, Trevisan B, Prelaj A, Ferrara R, Proto C, Signorelli D, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G. Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. *Lung Cancer*. 2019 Nov;137:38-42.
18. Pagani F, **Randon G**, Guarini V, Raimondi A, Prisciandaro M, Lobefaro R, Di Bartolomeo M, Sozzi G, de Braud F, Gasparini P, Pietrantonio F. The Landscape of Actionable Gene Fusions in Colorectal Cancer. *Int J Mol Sci*. 2019 Oct 25;20(21):5319.
19. Pietrantonio F, Lobefaro R, Antista M, Lonardi S, Raimondi A, Morano F, Mosconi S, Rimassa L, Murgioni S, Sartore-Bianchi A, Tomasello G, Longarini R, Farina G, Petrelli F, Gori S, **Randon G**, Corallo S, Pagani F, Guarini V, Palermo F, Martinetti A, Macagno M, Barault L, Perrone F, Tamborini E, Milione M, Di Nicolantonio F, Di Maio M, Fucà G, Di

- Bartolomeo M, de Braud F. Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. *Clin Cancer Res*. 2020 Mar 1;26(5):1017-1024.
20. Di Bartolomeo M, Morano F, Raimondi A, Miceli R, Corallo S, Tamborini E, Perrone F, Antista M, Niger M, Pellegrinelli A, **Randon G**, Pagani F, Martinetti A, Fucà G, Pietrantonio F; ITACA-S study group. Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. *Oncologist*. 2019 Nov 25;theoncologist.2019-0471.
 21. Prelaj A, Ferrara R, Rebuzzi SE, Proto C, Signorelli D, Galli G, De Toma A, **Randon G**, Pagani F, Viscardi G, Brambilla M, Trevisan B, Ganzinelli M, Martinetti A, Gallucci R, Di Mauro RM, Molino G, Zilembo N, Torri V, de Braud FM, Garassino MC, Lo Russo G. EPSiLoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. *Cancers (Basel)*. 2019 Dec 5;11(12):1954.
 22. Filippo Pietrantonio, Rona Yaeger, Alexa B. Schrock, **Giovanni Randon**, Sandra Romero-Cordoba, Daniele Rossini, Giovanni Fucà, Jeffrey S. Ross, Daisuke Kotani, Russell Madison, Seung Tae Kim, Lisa Salvatore, Alessandra Raimondi, Filippo Pagani, Beatrice Borelli, Federica Perrone, Maria Di Bartolomeo, Vincent A. Miller, Siraj M. Ali, Jeeyun Lee, Takayuki Yoshino, Filippo de Braud, Alfredo Falcone, Jaclyn F. Hechtman, Chiara Cremolini. Atypical RAS Mutations in Metastatic Colorectal Cancer. *JCO Precision Oncology* 2019 :3, 1-11.
 23. Pietrantonio F, **Randon G**, Romagnoli D, Di Donato S, Benelli M, de Braud F. Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. *Cancer Treat Rev*. 2020 Jan;82:101935.
 24. Raimondi A, Sepe P, Claps M, Maccauro M, Aliberti G, Pagani F, Apollonio G, **Randon G**, Peverelli G, Seregini E, Verzoni E, Procopio G. Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori. *Tumori*. 2020 Oct;106(5):406-412.
 25. Prelaj A, Lo Russo G, Proto C, Signorelli D, Ferrara R, Galli G, De Toma A, **Randon G**, Pagani F, Trevisan B, Ganzinelli M, Zilembo N, Montrone M, Longo V, Pesola F, Pizzutilo P, Del Bene G, Varesano N, Galetta D, Torri V, Garassino MC, Di Maio M, Catino A. DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. *Clin Lung Cancer*. 2020 Sep;21(5):e337-e348.
 26. Pietrantonio F, Loupakis F, **Randon G**, Raimondi A, Salati M, Trapani D, Pagani F, Depetris I, Maddalena G, Morano F, Corallo S, Prisciandaro M, Corti F, Guarini V, Bocconi A, Marra A, Belli C, Spallanzani A, Fassan M, Lonardi S, Curigliano G, Fucà G, Di Bartolomeo M, de Braud F. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. *Oncologist*. 2020 Sep;25(9):803-809.
 27. Pietrantonio F, Morano F, Niger M, Corallo S, Antista M, Raimondi A, Prisciandaro M, Pagani F, Prinzi N, Nichetti F, **Randon G**, Torchio M, Corti F, Ambrosini M, Palermo F, Palazzo M, Biamonte L, Platania M, Sposito C, Cosimelli M, Mazzaferro V, Pusceddu S, Cremolini C, de Braud F, Di Bartolomeo M. Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. *Clin Colorectal Cancer*. 2020 Sep;19(3):156-164.
 28. Schirripa M, Nappo F, Cremolini C, Salvatore L, Rossini D, Bensi M, Businello G, Pietrantonio F, **Randon G**, Fucà G, Boccaccino A, Bergamo F, Lonardi S, Dei Tos AP, Fassan M, Loupakis F. KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. *Clin Colorectal Cancer*. 2020 Sep;19(3):219-225.

29. **Randon G**, Pagani F, Pietrantonio F. MGMT Promoter Methylation as a Target In Metastatic Colorectal Cancer. Rapid Turnover and Use of Folates Alter its Study-Response. Clin Cancer Res. 2020 Jul 1;26(13):3495.
30. Pietrantonio F, Fucà G, Manca P, Pagani F, Raimondi A, Prisciandaro M, **Randon G**, Corti F, de Braud F, Cremolini C, Miceli R. Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECURSE trial. Tumori. 2021 Aug;107(4):353-359.
31. Mannavola F, Mandala M, Todisco A, Sileni VC, Palla M, Minisini AM, Pala L, Morgese F, Di Guardo L, Stucci LS, Guida M, Indini A, Quaglini P, Ferraresi V, Marconcini R, Tronconi MC, Rossi E, Nigro O, Ocelli M, Cortellini A, Quadrini S, Palmieri G, Pigozzo J, Ascierto PA, Vitale MG, Strippoli S, Ferrucci PF, Berardi R, **Randon G**, Cardone P, Schinzari G, Silvestris F, Tucci M. An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. Front Oncol. 2020 Sep 15;10:1652.
32. Bersanelli M, Buti S, Giannarelli D, Leonetti A, Cortellini A, Russo GL, Signorelli D, Toschi L, Milella M, Pilotto S, Bria E, Proto C, Marinello A, **Randon G**, Rossi S, Vita E, Sartori G, D'Argento E, Qako E, Giaiacopi E, Ghilardi L, Bettini AC, Rapacchi E, Mazzoni F, Lavacchi D, Scotti V, Ciccone LP, De Tursi M, Di Marino P, Santini D, Russano M, Bordi P, Di Maio M, Audisio M, Filetti M, Giusti R, Berardi R, Fiordoliva I, Cerea G, Pizzutilo EG, Bearz A, De Carlo E, Cecere F, Renna D, Camisa R, Caruso G, Ficorella C, Banna GL, Cortinovis D, Brighenti M, Garassino MC, Tiseo M. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. Lung Cancer. 2020 Dec;150:123-131.
33. Rutkowski P, Indini A, De Luca M, Merelli B, Mariuk-Jarema A, Teterycz P, Rogala P, Lugowska I, Cybulska-Stopa B, Labianca A, Di Guardo L, Del Vecchio M, Pigozzo J, **Randon G**, Corti F, Tondini CA, Rulli E, Mandala M. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. J Immunother Cancer. 2020 Nov;8(2):e001117.
34. Manca P, Corallo S, **Randon G**, Lonardi S, Cremolini C, Rimassa L, Bergamo F, Antoniotti C, Smirolto V, Zaniboni A, Murialdo R, Tampellini M, Tomasello G, Clavarezza M, Racca P, Antista M, Raimondi A, Prisciandaro M, Pagani F, Palermo F, Greco FG, Vaiani M, Di Bartolomeo M, de Braud F, Calareso G, Morano F, Pietrantonio F. Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. Eur J Cancer. 2021 Feb;144:31-40.
35. Raimondi A, Corallo S, Lonardi S, Antoniotti C, Rimassa L, Amatu A, Tampellini M, Racca P, Murialdo R, Clavarezza M, Zaniboni A, Toscano G, Tomasello G, Petrelli F, Antonuzzo L, Giordano M, Cinieri S, Longarini R, Niger M, Antista M, Ambrosini M, Pagani F, Prisciandaro M, **Randon G**, de Braud F, Di Bartolomeo M, Pietrantonio F, Morano F. Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. Support Care Cancer. 2021 Jul;29(7):3971-3980.
36. Manca P, Corallo S, Busico A, Lonardi S, Corti F, Antoniotti C, Procaccio L, Clavarezza M, Smirolto V, Tomasello G, Murialdo R, Sartore-Bianchi A, Racca P, Pagani F, **Randon G**, Martinetti A, Sottotetti E, Palermo F, Perrone F, Tamborini E, Prisciandaro M, Raimondi A, Di Bartolomeo M, Morano F, Pietrantonio F. The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. Clin Cancer Res. 2021 May 1;27(9):2505-2514.
37. De Toma A, Lo Russo G, Signorelli D, Pagani F, **Randon G**, Galli G, Prelaj A, Ferrara R, Proto C, Ganzinelli M, Zilembo N, de Braud F, Garassino MC. Uncommon targets in non-small cell lung cancer: Everyone wants a slice of

- cake. Crit Rev Oncol Hematol. 2021 Apr;160:103299.
38. Vernieri C, Nichetti F, Lalli L, Moschetti L, Giorgi CA, Griguolo G, Marra A, **Randon G**, Rea CG, Ligorio F, Scagnoli S, De Angelis C, Molinelli C, Fabbri A, Ferraro E, Trapani D, Milani A, Agostinetti E, Bernocchi O, Catania G, Vantaggiato A, Palleschi M, Moretti A, Basile D, Cinausero M, Ajazi A, Castagnoli L, Lo Vullo S, Gerratana L, Puglisi F, La Verde N, Arpino G, Rocca A, Ciccarese M, Pedersini R, Fabi A, Generali D, Losurdo A, Montemurro F, Curigliano G, Del Mastro L, Michelotti A, Cortesi E, Guarneri V, Pruneri G, Mariani L, de Braud F. Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). Clin Cancer Res. 2021 Jun 15;27(12):3443-3455.
 39. **Randon G**, Yaeger R, Hechtman JF, Manca P, Fucà G, Walch H, Lee J, Élez E, Seligmann J, Mussolin B, Pagani F, Germani MM, Ambrosini M, Rossini D, Ratti M, Salvà F, Richman SD, Wood H, Nanjangud G, Gloghini A, Milione M, Bardelli A, de Braud F, Morano F, Cremolini C, Pietrantonio F. EGFR Amplification in Metastatic Colorectal Cancer. J Natl Cancer Inst. 2021 Nov 2;113(11):1561-1569. J Natl Cancer Inst. 2021 Nov 2;113(11):1561-1569.
 40. Fucà G, Beninato T, Bini M, Mazzeo L, Di Guardo L, Cimminiello C, **Randon G**, Apollonio G, Bisogno I, Del Vecchio M, Lauria Pantano C, Di Nicola M, de Braud F, Del Vecchio M. The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy. Target Oncol. 2021 Jul;16(4):529-536.
 41. Battaglin F, **Randon G**, Raimondi A, Pagani F, Hiroyuki Arai, Pietrantonio F, Lenz HJ. Molecular Determinants of Gastrointestinal Cancers. Advances in Oncology, Volume 1, May 2021, Pages 311-325.
 42. Di Guardo L, **Randon G**, Corti F, Vallacchi V, Raimondi A, Fucà G, Bini M, Maurichi A, Patuzzo R, Gallino G, Mattavelli I, Ruggeri R, Angi M, Cossa M, Valeri B, Cimminiello C, Santinami M, Rivoltini L, de Braud F, Rodolfo M, Vecchio MD. Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma. Oncologist. 2021 Aug 6.
 43. Antoniotti C, Korn WM, Marmorino F, Rossini D, Lonardi S, Masi G, **Randon G**, Conca V, Boccaccino A, Tomasello G, Passardi A, Swensen J, Ugolini C, Oberley M, Tamburini E, Casagrande M, Domyuk V, Fontanini G, Giordano M, Abraham J, Spetzler D, Falcone A, Lenz HJ, Cremolini C. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. Eur J Cancer. 2021 Sep;155:73-84.

h-index: 10

17/11/2021
Giovanni Randon